|
1 |
Orexigen soars on license deal. Rexahn up on research article. BioDelivery reports positive FDA meeting
|
Thursday, 02 September 2010 |
BioMedReports.com Staff |
|
2 |
Transgenic silkworms could spin big profits
|
Thursday, 02 September 2010 |
M.E.Garza |
|
3 |
Is Athersys (NASDAQ:ATHX) still a buy?
|
Thursday, 02 September 2010 |
Patrick Crutcher |
|
4 |
Cardiome Pharma shares up on EU approval. Inhibitex reports positive Phase1a results. IVAX sells majority interest
|
Wednesday, 01 September 2010 |
BioMedReports.com Staff |
|
5 |
Obama administration appeals stem cell injunction
|
Wednesday, 01 September 2010 |
Jeremy Pelofsky for Reuters |
|
6 |
BMGP continues work on pathogen detection and disease diagnostics technology
|
Wednesday, 01 September 2010 |
M.E.Garza |
|
7 |
Celldex Therapuetics: Bottom play with upcoming catalysts
|
Wednesday, 01 September 2010 |
Patrick Crutcher |
|
8 |
FDA priority review status sends pSivida shares higher
|
Tuesday, 31 August 2010 |
BioMedReports.com Staff |
|
9 |
PDL BioPharma offering upcoming dividend
|
Tuesday, 31 August 2010 |
Patrick Crutcher |
|
10 |
Pluristem up on heart study. After the bell Alimera gets FDA priority review
|
Monday, 30 August 2010 |
BioMedReports.com Staff |
|
11 |
Buying opportunity with upcoming catalysts
|
Monday, 30 August 2010 |
Patrick Crutcher |
|
12 |
Outlook for Momenta Pharmaceuticals
|
Monday, 30 August 2010 |
Patrick Crutcher |
|
13 |
ImmunoGen sinks on cancer drug setback
|
Friday, 27 August 2010 |
BioMedReports.com Staff |
|
15 |
RxNews Recap for 08-26-10
|
Thursday, 26 August 2010 |
BioMedReports.com Staff |
|
17 |
Judge refuses to block generic blood thinner, Momenta Pharmaceuticals set to rise
|
Thursday, 26 August 2010 |
Patrick Crutcher |
|
18 |
Brain Tumor Advocates Remember Ted Kennedy One Year Later
|
Wednesday, 25 August 2010 |
Staff and Wire Reports |
|
19 |
RxNews Recap for 08-25-10
|
Wednesday, 25 August 2010 |
BioMedReports.com Staff |
